Brought to you by 
United Therapeutics, Supernus formulate UT15C
11 Mar 2015
Executive Summary
Shire’s drug delivery technology division Supernus Pharmaceuticals and United Therapeutics (develops drugs for cancer and cardiovascular and infectious diseases) will develop UT's UT15C, an oral prostacyclin analog. Supernus has licensed UT rights to use its EnSoTrol osmotic technology to formulate UT15C tablets for twice-daily administration for pulmonary arterial hypertension (PAD) and potentially other indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
United Therapeutics, Supernus formulate UT15C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice